@article{article, title = {{Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase}},
publisher = {{Elsevier}},
url = {{http://eprints.whiterose.ac.uk/163983/ }},
year = {{2020}},
month = {{9}},
author = {{Pivonello R and Fleseriu M and Newell-Price J and Bertagna X and Findling J and Shimatsu A and Gu F and Auchus R and Leelawattana R and Lee EJ and Kim JH et al}},
doi = {{10.1016/s2213-8587(20)30240-0}},
volume = {{8}},
journal = {{The Lancet Diabetes & Endocrinology}},
issue = {{9}},
pages = {{748-761}},
note = {{Accessed on 2025/05/21}}}